Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX versus TAZIDIME IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX versus TAZIDIME IN PLASTIC CONTAINER.
KEFUROX vs TAZIDIME IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP-3, leading to cell lysis and death. It is a beta-lactam antibiotic with activity against Gram-negative bacteria including Pseudomonas aeruginosa.
750 mg to 1.5 g intramuscularly or intravenously every 8 hours; for severe infections, 1.5 g intravenously every 6 to 8 hours.
1-2 g intravenously every 8 hours for most infections; up to 2 g every 6 hours for severe infections, particularly in neutropenic patients or those with cystic fibrosis.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function (Clcr >80 mL/min); prolonged to 10-20 hours in end-stage renal disease (Clcr <10 mL/min).
Terminal elimination half-life 1.7-2.0 hours in adults with normal renal function; prolonged to 12-30 hours in end-stage renal disease.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic